Malignant solid neoplasm, EGFR-mutated

Last updated on 2024-07-23: 1 regimens on this page 1 variants on this page

All lines of therapy

Erlotinib monotherapy

Regimen

Study	Dates of enrollment	Evidence
Hainsworth et al. 2018 (MyPathway)	2014-2016	Phase 2a, fewer than 20 pts in this arm

Biomarker eligibility criteria

• Gene: EGFR
• Alteration: nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
• Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
• Biomarker exclusions: EGFR exon 20 mutations

Targeted therapy

• Erlotinib (Tarceva) 150 mg PO once per day on days 1 to 28

28-day cycles

References

1. MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02091141